Kairos Pharma, Ltd. filed a Form 8-K with the SEC on November 3, 2026, disclosing three amendments to its equity line of credit purchase agreement with Helena Global Investment Opportunities I Ltd. and announcing a clinical data presentation by its President and Chief Scientific Officer.

Key Highlights

  • Third Amendment signed October 29, 2026: The option to use the equity line of credit with Helena was extended an additional year until December 31, 2028, according to the filing.
  • Second Amendment signed October 26, 2026: The applicable Pricing Period was shortened from three Trading Days to one Trading Day.
  • First Amendment signed February 4, 2026: The purchase price was adjusted to 97% of the average daily VWAP during the Pricing Period.
  • Combined amendments constitute material change: The filing states that the three amendments together "constitute a material change to the Purchase Agreement."
  • Clinical data presentation: President and Chief Scientific Officer Neil Bhowmick presented interim efficacy data from ongoing clinical trials evaluating ENV-105 (carotuximab) at the United Scientific Group's 11th International Conference on Cancer Research and Drug Development in Houston, Texas on November 3, 2026.
  • Exchange listing: Kairos Pharma's common stock, par value $0.001 per share, trades on NYSE American under the symbol KAPA (NYSE American:KAPA).

Kairos Pharma and Helena ELOC Amendments: Key Terms and Clinical Update

According to the filing, Kairos Pharma originally entered into a purchase agreement with Helena Global Investment Opportunities I Ltd. on November 12, 2024, establishing an equity line of credit. The company had previously disclosed that arrangement in its Quarterly Report on Form 10-Q filed on November 14, 2024. Three subsequent amendments have now been disclosed together in this filing because, the company stated, their combination constitutes a material change to the original Purchase Agreement.

The First Amendment, dated February 4, 2026, set the purchase price at 97% of the average daily VWAP during the Pricing Period. The Second Amendment, dated October 26, 2026, shortened the Pricing Period from three Trading Days to one Trading Day. The Third Amendment, dated October 29, 2026, extended the option to use the equity line of credit by an additional year, moving the expiration to December 31, 2028. The filing notes that the summary "does not purport to be complete" and is qualified by reference to the full exhibits filed with the report.

Separately, under Item 8.01, the company disclosed that Neil Bhowmick, its President and Chief Scientific Officer, presented interim efficacy data from ongoing clinical trials evaluating ENV-105 (carotuximab) at the 11th International Conference on Cancer Research and Drug Development in Houston, Texas on November 3, 2026. The filing notes that the press release and slide presentation furnished as exhibits "shall not be deemed 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934.

What Was Disclosed

Kairos Pharma disclosed three amendments to its equity line of credit agreement with Helena, collectively representing a material change, and announced a clinical data presentation by its President and Chief Scientific Officer regarding ENV-105 (carotuximab) interim efficacy data.